The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN).

Robert I. Haddad,Kevin J. Harrington,Lisa Licitra,Amanda Psyrri,Nabil F. Saba,Natasa Rajicic,Binaifer R. Balsara,Michael R. Kurman,Catherine Rose Scholz,Antonio Gualberto,Alan Loh Ho

The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN).

2020

Robert I. Haddad
Kevin J. Harrington
Lisa Licitra
Amanda Psyrri
Nabil F. Saba
Natasa Rajicic
Binaifer R. Balsara
Michael R. Kurman
Catherine Rose Scholz
Antonio Gualberto
Alan Loh Ho

TPS6593Background: HRAS mutations define a unique molecular subset of ~ 5% of HNSCC. Evidence suggests that these tumors respond poorly to standard systemic therapy but the impact of HRAS missense ...

Keywords:

in patient
Tipifarnib
Head and neck squamous-cell carcinoma
first line
HRAS
Pathology
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations